Biological agents for the treatment of IBD are the result of both the explo
sion of knowledge precipitated by the techniques of molecular biology, and
by the ability to use these same techniques to produce agents. Thus, there
has been a greatly facilitated translation of basic knowledge into clinical
therapy. An astounding number of biologic agents are currently in developm
ent for the treatment of IBD and other immune-mediated conditions. These in
clude native microbiologic preparations isolated for beneficial properties,
recombinant cytokines and anticytokines, monoclonal antibodies, antisense
oligonucleotides, and in the future, somatic gene therapy. This work seeks
to describe the principles and techniques of biologic agent development, as
well as prime sites of action targeted by these agents.
Recent advances in the techniques of molecular biology have made possible u
nprecedented progress in the treatment of many conditions. The techniques o
f molecular biology have provided new methods of drug discovery and at the
same time have elucidated new therapeutic targets. Most notable has been th
e progress made in the treatment of chronic inflammatory and immune mediate
d conditions, including inflammatory bowel disease. This paper is intended
to highlight the methodological principles behind biologic agents, methods
of discovery and production, and to highlight potential therapeutic targets
for these new agents.